Cancer Biospecimen Acquisition and Biorepository

AECC癌症生物标本采集和生物储存库资源（CBABR）的目标是提供一个符合NCI癌症研究高质量生物标本最佳实践的集中单元。CBABR监督从实体肿瘤和血液学肿瘤中采购恶性、良性、病变和未受累（正常）组织，供AECC和其他研究人员使用。CBABR是通过将多个联合癌症相关的机构生物库整合成一个有凝聚力的面向癌症的组织获取和储存生物库而组织起来的，这是未来样本收集的核心。CBABR是AECC，爱因斯坦CTSA和其他NIH资助的爱因斯坦中心的共同努力，并得到了几个机构倡议的支持，包括爱因斯坦的临床合作伙伴Montefiore医学中心使用的普遍选择同意程序，与Montefiore外科病理学合作的专门人员组织采集，临床研究信息学支持将样本与医疗和研究记录联系起来，和专用的安全存储空间，利用最先进的节能冷冻技术。已经开发了一个基于网络的应用程序，使研究人员能够确定CBABR中是否存在具有必要表型特征的组织。CBABR的重点是头颈癌、乳腺癌、结肠癌、肺癌、宫颈癌和卵巢癌、神经内分泌肿瘤和血液肿瘤。它目前拥有67704个样本，其中包括自2011年底建立新的CBABR以来收集的5704个样本，所有这些样本都可供调查人员使用。CBABR过程包括患者在初始癌症评估时的知情同意，计划中的普遍“选择加入”

The goal of the AECC Cancer Biospecimen Acquisition and Biorepository Resource (CBABR) is to provide a centralized unit that meets the best practices of the NCI for high quality biospecimens for cancer research. The CBABR oversees the procurement of malignant, benign, diseased and uninvolved (normal) tissues from both solid and hematological tumors for use by AECC and other investigators. The CBABR has been organized through the consolidation of multiple federated cancer associated Institutional biobanks into a cohesive cancer oriented tissue acquisition and storage biobank that is the nucleus for prospective sample collection. The CBABR is a joint effort of AECC, the Einstein CTSA and other NIH funded centers at Einstein and is supported by several Institutional initiatives including a universal opt-in consent process in use by Einstein's clinical partner, Montefiore Medical Center, dedicated staffing for tissue acquisition in cooperation with Montefiore Surgical Pathology, Clinical Research Informatics support linking samples to medical and research records, and dedicated secure storage space utilizing the most advanced energy efficient freezer technology. A web-based application has been developed that allows investigators to determine if tissue exists in the CBABR with necessary phenotypic characteristics for their studies. The CBABR focus has been on head and neck cancer, breast, colon, lung, cervical and ovarian, neuroendocrine tumors, and hematological tumors. It currently houses 67,704 samples, including 5,704 samples collected since the institution of the new CBABR in late 2011, all of which are available for use by investigators. The CBABR process encompasses patient informed consent at initial cancer evaluation, planned universal "opt-in" consent procedures, patient medical and health information that is annotated to the biospecimens, centralized management of specimen collection, processing and storage, and multiple levels of security and protection of the resource through the parent CTSA biorepository including 24/7 monitoring and alarmed redundant backups. A CBABR Scientific Review Board (SRB) has been constituted to evaluate scientific and technical merit of applications for use of biospecimens that reports to the AECC Protocol Review and Monitoring Committee (PRMC) to approve and, when necessary, prioritize proposed tissue usage. Mechanisms for requested collaborations from outside investigators have been established as well. An institutional initiative will track the informed consent process and perform follow up queries on contributors to the CBSR to assess patient knowledge and satisfaction.